Fluid Pharma, in collaboration with the Cancer Research UK Cambridge Institute (CRUK CI), has been awarded a £168K Partnerships and Impact Award from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs).

The funded project — “Characterization and Application of Tamoxifen Taste-Masked Beads in Preclinical Research” — is led by CRUK CI and supports the validation of Fluid Pharma’s innovative tamoxifen formulation, Tat-Fit™: Tasteful Tamoxifen for Inducible Transgenesis.

Tamoxifen is widely used to control gene expression in transgenic mouse models. However, there is currently no standardised method for dosing tamoxifen, and commonly used approaches can raise animal welfare concerns.

Building on prior support from NC3Rs CRACK IT funding and the Mary Lyon Centre at MRC Harwell, Fluid Pharma developed taste-masked tamoxifen micro-pellets (Tat-Fit™) that allow tamoxifen to be administered orally by mixing with standard diet. This approach enables stress-free, consistent dosing and reduces the need for invasive administration techniques.

The new partnership with CRUK CI will further validate this technology and build confidence in its adoption as a welfare-focused refinement for administering tamoxifen in transgenic research.

To read the full press release on this award, please visit:

https://nc3rs.org.uk/news/ps12m-awarded-through-inaugural-partnerships-and-impact-funding-call